Amgen's dazodalibep meets main goal in late-stage Sjogren's trial
Amgen's dazodalibep hit its primary endpoint in a late-stage Sjogren's disease trial, showing significant improvement at week 48.
Amgen has reported that its investigational drug dazodalibep achieved the primary objective of a late-stage clinical trial in Sjogren's disease, a condition in which the body's moisture-producing glands come under attack.
The company said the therapy produced a statistically significant and clinically meaningful reduction in disease activity among patients at week 48. Sjogren's disease is known to cause widespread dryness of the eyes, mouth and other areas of the body, and is often accompanied by fatigue and persistent pain.
According to the National Institutes of Health, the condition affects roughly 1% of the global population and is seen predominantly in women.
On safety, Amgen said the majority of adverse events observed during the trial were mild to moderate, and only a small number of participants stopped treatment as a result.
The company plans to share detailed results from the study at a forthcoming medical conference. The trial itself is scheduled to conclude in the fourth quarter of 2026.
Sjogren's disease currently has no approved treatments in the United States. Other pharmaceutical companies, including Novartis and Johnson & Johnson, are also working on therapies for the condition.